Clinical Trial Update: Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pembrolizumab in combination with lenvatinib for metastatic or recurrent cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• LENVIMA (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Cervix Cancer, Cervical Cancer | Phase 2 | Status: RECRUITING